I-Mab Announces Outcome in Arbitration Relating to Agreements With Tracon Pharma
I-Mab Announces Outcome in Arbitration Relating to Agreements With Tracon Pharma
天境生物公佈與Tracon Pharma協議有關的仲裁結果
I-Mab (the "Company") (NASDAQ:IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced the positive outcome of its arbitration with TRACON Pharmaceuticals ("Tracon") relating to (1) the collaboration agreement to co-develop I-Mab's proprietary CD73 antibody, uliledlimab (TJD5) (the "TJD5 Agreement"), and (2) the collaboration agreement to potentially co-develop I-Mab's bi-specific antibodies (the "BsAb Agreement").
致力於發現、開發和商業化新型生物製藥的臨牀階段生物製藥公司i-Mab（“公司”）（納斯達克股票代碼：IMAB）今天宣佈與TRACON Pharmicals（“TRACON”）就（1）共同開發i-Mab專有CD73抗體uliledlimab（TJD5）的合作協議的仲裁取得了積極結果協議”）和（2）可能共同開發I-Mab雙特異性抗體的合作協議（“bsaB協議”）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。